GuidelineZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2026
[Interpretation of key updates of the 2026 version of the APASL clinical practice guidelines for the management of chronic hepatitis B].
Guideline in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The Asia-Pacific region has the heavy burden of chronic hepatitis B. In 2026, the Asia-Pacific Association for the Study of the Liver (APASL) updated its clinical practice guidelines for the management of chronic hepatitis B. The recommendations in this version of the guideline are formulated around focusing 13 core areas: vaccination and universal screening strategies, an established system of progressive treatment goals, pathways for stratified assessment of liver fibrosis based on resource availability, expansion of antiviral therapy indications, and advocacy of proactive treatment strategies. Incorporating metabolic risk factors into long-term care and managing co-existing metabolic dysfunction-associated fatty liver disease at the same time emphasizes shared decision-making between patients and clinicians and the use of new technologies in risk assessment, which optimizes the link between diagnosis and treatment and improves long-term clinical outcomes for patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.